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Summary: In this study, we used solid-phase extraction with Sep-Pak and a 
liquid-liquid extraction with methylene chloride as two primary methods of 
extracting FK506 from plasma. The extracts were either analyzed directly by 
enzyme-linked immunosorbent assay (ELISA) or subjected to high-perfor-
mance liquid chromatography (HPLC) separation and different fractions were 
analyzed by ELISA. Serial blood samples were obtained from four kidney 
transplant patients and four patients who underwent liver transplantation, from 
day I until day 30-35 posttransplantation. There was no significant difference 
in the FK506 plasma concentration as measured by all four methods in normal 
transplant patients. However, in liver transplant patients, the solid-phase ex-
traction method gave higher FK506 concentrations than the methylene chlo-
ride extraction during the early postoperative period. The concentrations mea-
sured after methylene chloride extraction were higher than that after HPLC-
ELISA. This higher FK506 concentration measured by direct ELISA could be 
attributed to possible cross-reacting metabolites that were present in the 
plasma of patients with abnormal liver functions. Once liver function returns to 
normal, all four methods give identical plasma concentrations for FK506. Key 
Words: FK506--Immunosuppression. 
FK506 is currently under clinical investigation as 
an immunosuppressive agent in various organ trans-
plant patients (1). It is a very potent compound that 
appears to have significant nephrotoxicity as a ma-
jor side effect (2). Pharmacokinetic studies of 
FK506 have shown that there is a large inter- and 
intraindividual variation in its kinetics in organ 
transplant patients (3,4). These factors necessitate 
routine monitoring of plasma FK506 concentration 
in transplant patients in an effort to optimize FK506 
therapy. Plasma FK506 concentrations are cur-
rently measured at the University of Pittsburgh 
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Medical Center by an enzyme-linked immunosor-
bent assay (ELISA) method after a solid phase ex-
traction (5,6). In addition, FK506 can also be mea-
sured in whole blood by a radioreceptor assay (7), 
high-performance liquid chromatography-mass 
spectrometry (HPLC-MS) assay (8,9), Abbott IMx 
method (10), and in serum by a combined HPLC-
ELISA method (11). A recent study has shown that 
FK506 concentrations, as measured by ELISA af-
ter a solid phase extraction, are higher than those 
measured after a liquid-liquid extraction, using 
methylene chloride (12,13). The primary objective 
of this study was to evaluate the effect of two dif-
ferent extraction procedures for measurement of 
trough FK506 concentrations in plasma samples ob-
tained from liver and kidney transplant patients in 
comparison to a specific analytical procedure that 
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uses a HPLC separation step, to separate potential 
FKS06 metabolites from FK506 before use of 
ELISA. 
MATERIALS AND METHODS 
Materials 
FK506 drug, monoclonal antibody for FKS06, 
and FKS06 peroxidase enzyme cOIijugate were sup-
plied by Fujisawa Pharmaceuticals (Osaka, Japan). 
Anti-mouse IgG was purchased from Atlantic Anti-
bodies (Stillwater, MN, U.S.A.). C-18 Sep-Pak col-
umns were obtained from Waters (Milford, MA, 
U.S.A.). O-Phenylenediamine (OPD) was pur-
chased from Sigma (St. Louis, MO, U.S.A.). Other 
reagents were purchased from Fisher Scientific 
(Pittsburgh, PA, U.S.A.). 
Methods 
Clinical Protocol 
Daily trough blood samples were collected from 
four liver and four kidney transplant patients from 
day 1 till 30-3S days posttransplantation. Biochem-
ical parameters characterizing kidney function (se-
rum creatinine) and liver function (bilirubin, aspar-
tate aminotransferase, alanine aminotransferase) 
were measured in these patients over the entire 
study period. Blood samples obtained for FK506 
measurement were incubated at 37° for 4S min. The 
plasma was separated at 37°C and extracted by the 
methods described below and subjected to ELISA 
analysis. 
Solid-Phase Extraction 
Plasma (100 fl.l) in duplicate was acidified with 1 
ml of 0.1 N HCI and passed through a C-18 Sep-Pak 
cartridge which was prewashed with 4% acetic acid. 
After an additional wash with 4% acetic acid, 
FKS06 was eluted with 2 ml methanol (6). The 
methanol was evaporated under nitrogen and the 
FK506 content was analyzed by ELISA. 
Liquid-Liquid Extraction with Methylene Chloride 
Plasma (100 fl.1) in duplicate was acidified with 1 
ml of 0.1 N HCI and extracted with S ml of methy-
lene chloride. This procedure is a minor modifica-
tion of the procedure described by Kobayashi et al. 
(12). The organic layer was collected and evapo-
rated under nitrogen at room temperature and 
FKS06 content was analyzed by ELISA. 
High-Performance Liquid Chromatography 
Plasma extracts prepared by solid phase extrac-
tion and methylene chloride extraction were dis-
solved in methanol and subjected to HPLC separa-
tion. HPLC was performed on a Waters 600E mul-
tisolvent delivery system equipped with a system 
controller and a 994 photodiode array detector. For 
the separation of FKS06, its metabolites, and en-
dogenous compounds, we used 3.9-mm ID x IS.0-
cm long analytical column filled with fl-BondaPak 
C-18 (Catalog no. 86684, Waters Associates). The 
column temperature was set to 60°C for the analy-
sis. A mobile phase consisting of 80% methanol and 
20% H20 (acidified to pH 6.0 with HCI) was used to 
elute different components from the column at a 
flow rate of 0.8 ml/min. The eluents were monitored 
at 214 nm. The retention time of FKS06 was 4.8 min 
under these conditions. Two fractions were col-
lected from 0-3.6 and 3.6-6 min with greater than 
99% of the parent FK506 being collected in the sec-
ond fraction. Both fractions were evaporated under 
nitrogen and the residue analyzed for FKS06 using 
ELISA. 
RESULTS 
The biochemical profiles of the patients studied 
are listed in Table 1. Patients received intravenous 
FKS06 at a dose of 0.05 mg/kg/day as a continuous 
TABLE 1. Biochemical profile in four liver and four 
kidney transplant patients 
Creatinine Bilirubin· 
(mg/dl) (mg/dl) 
Patient 
name c d c d 
Kidney 
HB 11.8 1.9 0.4 0.3 
HG 10.0 2.3 0.4 1.2 
GW 8.8 3.0 1.3 0.8 
FB 7.5 1.9 0.5 0.4 
Liver 
MK 1.8 1.9 2.8 0.9 
JR 1.9 1.4 7.1 0.9 
BC 0.3 1.3 1.8 0.7 
AA 0.4 0.8 3.1 1.0 
a Aspartate aminotransferase. 
b Alanine aminotransferase. 
ASTa 
(lUlL) 
c d 
31 12 
51 46 
20 36 
15 9 
952 21 
194 11 
69 49 
59 30 
C During the immediate postoperative period. 
d Four weeks after transplantation. 
ALTb 
(lUlL) 
c 
21 
80 
10 
32 
1,188 
303 
1,423 
159 
d 
51 
86 
56 
20 
29 
30 
61 
31 
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infusion during the immediate postoperative time 
and for up to 3-7 days. They were converted to oral 
therapy at a dose of 0.15 mg/kg day as soon as they 
were ready for oral intake. All kidney transplant 
patients had normal liver function tests and all liver 
transplant patients had normal kidney function 
throughout the entire course of study. The interday 
coefficient of variation of the HPLC-ELISA 
method is 16.5% (n = 20). Because HPLC-ELISA 
after Sep-Pak and methylene chloride were similar 
(? = 0.95), these values were averaged and com-
pared with direct ELISA. The regression equation 
of the FK506 concentrations measured by methy-
lene chloride-ELISA versus Sep-Pak-ELISA is 
given as follows: methylene chloride method Cng/ 
ml) = 0.066 + 0.91 [Sep-Pak method (ng/ml)] , ? = 
0.94; p < 0.01. 
In all the kidney patients, the concentration of 
FK506 in plasma was very similar when measured 
by ELISA following Sep-Pak or methylene chloride 
extraction as indicated in Fig. 1. In addition, sepa-
ration of potential FK metabolites from parent 
FK506 by HPLC and subsequent ELISA assay also 
gave similar FK506 concentrations. In this group of 
patients, there was no difference in FK506 concen-
tration as measured by the three methods, irrespec-
tive of whether the patient was on intravenous or 
oral FK506 therapy, or irrespective of the func-
tional status of the kidney. 
In liver transplant patients, during the immediate 
postoperative period, the bilirubin concentration 
was high and decreased to normal values over a 
time period, as indicated in Fig. 2. In three of the 
patients (JR, MK, AA), during the immediate post-
operative period, serum bilirubin was elevated, and 
FK506 concentrations measured by Sep-Pak-
ELISA was higher in comparison with methylene 
chloride-ELISA. However, both of these estimates 
were also higher than the values obtained by 
HPLC-ELISA. As the bilirubin concentrations re-
turned toward normal values, the concentration of 
FK506 measured by all three methods was almost 
identical. In one patient (BC), however, from day 1 
posttransplant all the assay methods provided the 
same values. The highest total bilirubin in this pa-
tient was only 1.8 mg/dl which is indicative of near 
normal function of the liver. In this patient, on days 
10 and 32, FK506 concentrations were significantly 
elevated as measured by all three methods. 
DISCUSSION 
Over the past several years, we have been using 
a Sep-Pak extraction procedure for measuring 
plasma concentrations of FK506. Recently, a meth-
ylene chloride extraction procedure has been re-
ported for measurement of FK506 in plasma (12). 
This procedure tends to give lower values in com-
parison to the Sep-Pak extraction procedure. It is 
believed that this is due to accumulated FK506 me-
tabolites that co-elute in the solid-phase extraction 
and that are not extracted by the methylene chlo-
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FIG. 1. Plasma FK506 concentrations as mea-
sured by Sep-Pak ELISA (0), methylene chlo-
ride ELISA (0), HPLC ELISA (6), and creati-
nine (e) in four kidney transplant patients, 
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ride. In order to evaluate the specificity of the Sep-
Pak and methylene chloride methods, we developed 
an HPLC-ELISA method for measuring parent 
FK506 in plasma. Our results indicate that in pa-
tients with normal liver function, concentrations of 
FK506, as measured by a specific HPLC-ELISA 
method, is similar to the concentrations measured 
by Sep-Pak-ELISA or methylene chloride-ELISA. 
This is true independently of whether the organ 
transplanted is kidney or liver. This is perhaps due 
to the fact that in patients with normal hepatic func-
tion, very little, if any, of the metabolites of FK506 
accumulate in the plasma and are, therefore, ex-
tracted from plasma. In liver transplant patients, 
during the immediate postoperative period when 
the liver function is not normal, as indicated by el-
evated bilirubin concentrations, the Sep-Pak proce-
dure gives the highest values and HPLC-ELISA 
gives the lowest, indicating accumulation ofthe me-
tabolites in these patients. These metabolites cross-
react with the monoclonal antibody used in the 
ELISA procedure. Once hepatic function im-
proves, the liver is able to clear most of the metab-
olites of FK506 with the result that there is no sig-
nificant difference between concentrations mea-
sured by the different methods. 
Our results also indicate that changes in kidney 
function, as measured by serum creatinine, did not 
have any influence on the FK506 concentration as 
measured by all three methods. This suggests that 
only a very small amount of FK506 metabolites are, 
in fact, excreted through the kidney. This fact is 
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supported by our previous observation of renal 
clearance of FK506 to be < 1 % of total body clear-
ance (4). 
The observation that FK506 levels, measured by 
the three different methods, are also independent of 
the route of administration, suggest the following: 
(a) There is no route-dependent metabolism of 
FK506, indicating minimal gut metabolism; and/or 
(b) any metabolite produced in the small intestine 
minimally cross-reacts with the monoclonal anti-
body used in the ELISA assay. Recent evidence 
points to the potential for gut metabolism of FK in 
humans (9). However, the extent of cross reactivity 
of the metabolites produced in the small intestine 
with the monoclonal antibody used in ELISA is not 
known at this time. 
CONCLUSIONS 
A solid phase extraction method and a liquid-
liquid extraction method using methylene chloride 
were studied, in comparison to an HPLC method 
for measuring FK506 plasma concentrations. In 
kidney transplant patients, there was no difference 
in FK506 concentrations obtained by the different 
procedures used. In liver transplant patients, the 
solid-phase extraction method gave higher FK506 
concentrations than the methylene chloride extrac-
tion only in patients with abnormal liver function. 
HPLC separation procedure before ELISA indi-
cated that the elevated FK506 levels from solid-
phase-ELISA and methylene chloride-ELISA were 
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due to cross-reacting metabolites that were present 
in these patients. Presently, at our medical center 
patients are maintained at trough plasma concentra-
tions between 0.5 and 2.0 ng/ml. Therapeutic range 
for FK506 concentrations in plasma is independent 
of the assay method used in patients with normal 
liver function. However, in the presence of liver 
dysfunction, both methylene chloride-ELISA and 
Sep-Pak-ELISA will measure some of the metabo-
lites and this should be kept in mind in interpreting 
the data. 
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